Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in HIV Immunological Nonresponders
NCT05244473Phase 1Withdrawn
- Sponsor
- Seagen Inc.
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in human immunodeficiency virus infection (HIV) comparing Brentuximab vedotin + ART with Placebo + ART (2 arms). Primary endpoints: Number of participants with adverse events, Number of participants with laboratory abnormalities at 1 year and 1 more. Planned start Dec 2022; status: withdrawn.
02
Drugs
brentuximab vedotin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05244473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244473.